JP2004505912A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004505912A5 JP2004505912A5 JP2002517052A JP2002517052A JP2004505912A5 JP 2004505912 A5 JP2004505912 A5 JP 2004505912A5 JP 2002517052 A JP2002517052 A JP 2002517052A JP 2002517052 A JP2002517052 A JP 2002517052A JP 2004505912 A5 JP2004505912 A5 JP 2004505912A5
- Authority
- JP
- Japan
- Prior art keywords
- guanidine
- nitrobenzylideneamino
- composition according
- guanidine acetate
- acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 description 22
- 229940002612 prodrug Drugs 0.000 description 9
- 239000000651 prodrug Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 6
- 208000022531 anorexia Diseases 0.000 description 4
- 206010061428 decreased appetite Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000004378 Melanocortin Receptors Human genes 0.000 description 2
- 108090000950 Melanocortin Receptors Proteins 0.000 description 2
- 108010008364 Melanocortins Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 201000001880 Sexual dysfunction Diseases 0.000 description 2
- 206010040829 Skin discolouration Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 208000030381 cutaneous melanoma Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000002865 melanocortin Substances 0.000 description 2
- -1 methoxy, hydroxy Chemical group 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 231100000872 sexual dysfunction Toxicity 0.000 description 2
- 230000036299 sexual function Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 201000003708 skin melanoma Diseases 0.000 description 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 2
- UEYMVLYFTKJDHE-UHFFFAOYSA-N 2-[(2,3,4-trimethoxyphenyl)methylideneamino]guanidine;hydrochloride Chemical compound Cl.COC1=CC=C(C=NNC(N)=N)C(OC)=C1OC UEYMVLYFTKJDHE-UHFFFAOYSA-N 0.000 description 1
- WHSMHQQGLVVQJZ-UHFFFAOYSA-N 2-[(2,3-dimethoxy-5-nitrophenyl)methylideneamino]guanidine;hydrochloride Chemical compound Cl.COC1=CC([N+]([O-])=O)=CC(C=NNC(N)=N)=C1OC WHSMHQQGLVVQJZ-UHFFFAOYSA-N 0.000 description 1
- HDLADIYRGZTSTC-UHFFFAOYSA-N 2-[(2-hydroxy-4-methoxy-5-nitrophenyl)methylideneamino]guanidine Chemical compound COC1=CC(O)=C(C=NNC(N)=N)C=C1[N+]([O-])=O HDLADIYRGZTSTC-UHFFFAOYSA-N 0.000 description 1
- ZPPQPYVAWOBQSX-UHFFFAOYSA-N 2-[(3-bromo-2,6-dinitrophenyl)methylideneamino]guanidine hydrochloride Chemical compound Cl.NC(=N)NN=CC1=C([N+]([O-])=O)C=CC(Br)=C1[N+]([O-])=O ZPPQPYVAWOBQSX-UHFFFAOYSA-N 0.000 description 1
- QZPYZNYEFBAJQK-UHFFFAOYSA-N 2-[(3-chloro-4-methoxy-5-nitrophenyl)methylideneamino]guanidine Chemical compound COC1=C(Cl)C=C(C=NNC(N)=N)C=C1[N+]([O-])=O QZPYZNYEFBAJQK-UHFFFAOYSA-N 0.000 description 1
- FBQIPMYAOJAAAR-UHFFFAOYSA-N 2-[(3-iodophenyl)methylideneamino]guanidine;hydrochloride Chemical compound Cl.NC(=N)NN=CC1=CC=CC(I)=C1 FBQIPMYAOJAAAR-UHFFFAOYSA-N 0.000 description 1
- UTPLZJPUVNVQNQ-UHFFFAOYSA-N 2-[(5-bromo-2-hydroxy-3-nitrophenyl)methylideneamino]guanidine hydrochloride Chemical compound Cl.NC(=N)NN=CC1=CC(Br)=CC([N+]([O-])=O)=C1O UTPLZJPUVNVQNQ-UHFFFAOYSA-N 0.000 description 1
- WSNKYMRJFVHMND-UHFFFAOYSA-N 2-[(5-bromo-2-methoxy-3-nitrophenyl)methylideneamino]guanidine;hydrochloride Chemical compound Cl.COC1=C(C=NNC(N)=N)C=C(Br)C=C1[N+]([O-])=O WSNKYMRJFVHMND-UHFFFAOYSA-N 0.000 description 1
- TVSCNSTYGZWZMS-UHFFFAOYSA-N 2-[(diaminomethylidenehydrazinylidene)methyl]benzenesulfonic acid;hydrochloride Chemical compound Cl.NC(=N)NN=CC1=CC=CC=C1S(O)(=O)=O TVSCNSTYGZWZMS-UHFFFAOYSA-N 0.000 description 1
- FZGICYVEFPCIJR-UHFFFAOYSA-N CC(O)=O.COc1cc(O)c(C=NNC(N)=N)c(OC)c1 Chemical compound CC(O)=O.COc1cc(O)c(C=NNC(N)=N)c(OC)c1 FZGICYVEFPCIJR-UHFFFAOYSA-N 0.000 description 1
- NKTPTBRFGPRMNV-UHFFFAOYSA-N CC(O)=O.COc1ccc(C=NNC(N)=N)c(O)c1 Chemical compound CC(O)=O.COc1ccc(C=NNC(N)=N)c(O)c1 NKTPTBRFGPRMNV-UHFFFAOYSA-N 0.000 description 1
- WXUSRYRMPVIFSJ-UHFFFAOYSA-N Cl.CC1=CC(O)=C(C=NNC(N)=N)C=C1[N+]([O-])=O Chemical compound Cl.CC1=CC(O)=C(C=NNC(N)=N)C=C1[N+]([O-])=O WXUSRYRMPVIFSJ-UHFFFAOYSA-N 0.000 description 1
- WYIQRGNHAFDUJB-UHFFFAOYSA-N Cl.COC1=CC([N+]([O-])=O)=CC(C=NNC(N)=N)=C1O Chemical compound Cl.COC1=CC([N+]([O-])=O)=CC(C=NNC(N)=N)=C1O WYIQRGNHAFDUJB-UHFFFAOYSA-N 0.000 description 1
- GOKZZNWSZZAMPR-UHFFFAOYSA-N Cl.COC1=CC=C([N+]([O-])=O)C(C=NNC(N)=N)=C1[N+]([O-])=O Chemical compound Cl.COC1=CC=C([N+]([O-])=O)C(C=NNC(N)=N)=C1[N+]([O-])=O GOKZZNWSZZAMPR-UHFFFAOYSA-N 0.000 description 1
- NNSCTDFNTPTKDH-UHFFFAOYSA-N Cl.NC(=N)NN=CC1=C(Cl)C=CC([N+]([O-])=O)=C1[N+]([O-])=O Chemical compound Cl.NC(=N)NN=CC1=C(Cl)C=CC([N+]([O-])=O)=C1[N+]([O-])=O NNSCTDFNTPTKDH-UHFFFAOYSA-N 0.000 description 1
- JVNDWFBBXAJJMP-UHFFFAOYSA-N acetic acid 2-[(3,5-dinitrophenyl)methylideneamino]guanidine dihydrate Chemical compound O.O.CC(O)=O.NC(=N)NN=Cc1cc(cc(c1)[N+]([O-])=O)[N+]([O-])=O JVNDWFBBXAJJMP-UHFFFAOYSA-N 0.000 description 1
- HXTUKJJBEGTJPF-UHFFFAOYSA-N acetic acid;2-[(2,3-difluorophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.NC(N)=NN=CC1=CC=CC(F)=C1F HXTUKJJBEGTJPF-UHFFFAOYSA-N 0.000 description 1
- PQYJMHHAGLHLAW-UHFFFAOYSA-N acetic acid;2-[(2,3-dimethoxy-5,6-dinitrophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.COC1=CC([N+]([O-])=O)=C([N+]([O-])=O)C(C=NN=C(N)N)=C1OC PQYJMHHAGLHLAW-UHFFFAOYSA-N 0.000 description 1
- XUHYROIDEFAERS-UHFFFAOYSA-N acetic acid;2-[(2,3-dimethoxy-5-nitrophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.COC1=CC([N+]([O-])=O)=CC(C=NN=C(N)N)=C1OC XUHYROIDEFAERS-UHFFFAOYSA-N 0.000 description 1
- MHJUAHCGSDHUCN-UHFFFAOYSA-N acetic acid;2-[(2,4-dimethoxy-5-nitrophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.COC1=CC(OC)=C([N+]([O-])=O)C=C1C=NN=C(N)N MHJUAHCGSDHUCN-UHFFFAOYSA-N 0.000 description 1
- AYGPUXPCAFIMIG-UHFFFAOYSA-N acetic acid;2-[(2-bromo-4-nitrophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.NC(N)=NN=CC1=CC=C([N+]([O-])=O)C=C1Br AYGPUXPCAFIMIG-UHFFFAOYSA-N 0.000 description 1
- QDGQJMCEAHTZKE-UHFFFAOYSA-N acetic acid;2-[(2-bromo-5-nitrophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.NC(N)=NN=CC1=CC([N+]([O-])=O)=CC=C1Br QDGQJMCEAHTZKE-UHFFFAOYSA-N 0.000 description 1
- YQHLHWOPFVZJAT-UHFFFAOYSA-N acetic acid;2-[(2-fluoro-5-nitrophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.NC(N)=NN=CC1=CC([N+]([O-])=O)=CC=C1F YQHLHWOPFVZJAT-UHFFFAOYSA-N 0.000 description 1
- GWMVDBKCYKUESY-UHFFFAOYSA-N acetic acid;2-[(2-iodophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.NC(N)=NN=CC1=CC=CC=C1I GWMVDBKCYKUESY-UHFFFAOYSA-N 0.000 description 1
- YKUUEEAVWUIRHZ-UHFFFAOYSA-N acetic acid;2-[(3,4-difluorophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.NC(N)=NN=CC1=CC=C(F)C(F)=C1 YKUUEEAVWUIRHZ-UHFFFAOYSA-N 0.000 description 1
- BIBSTXHVXAUVSG-UHFFFAOYSA-N acetic acid;2-[(3,5-dichloro-2-nitrophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.NC(N)=NN=CC1=CC(Cl)=CC(Cl)=C1[N+]([O-])=O BIBSTXHVXAUVSG-UHFFFAOYSA-N 0.000 description 1
- BGMARYPSDDQNRG-UHFFFAOYSA-N acetic acid;2-[(3,5-dichloro-4-methoxyphenyl)methylideneamino]guanidine Chemical compound CC(O)=O.COC1=C(Cl)C=C(C=NN=C(N)N)C=C1Cl BGMARYPSDDQNRG-UHFFFAOYSA-N 0.000 description 1
- MTEYXIZIIAMIRC-UHFFFAOYSA-N acetic acid;2-[(3,6-dichloro-2-nitrophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.NC(N)=NN=CC1=C(Cl)C=CC(Cl)=C1[N+]([O-])=O MTEYXIZIIAMIRC-UHFFFAOYSA-N 0.000 description 1
- LDDRALBTDIPTAT-UHFFFAOYSA-N acetic acid;2-[(3-bromo-4-fluorophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.NC(N)=NN=CC1=CC=C(F)C(Br)=C1 LDDRALBTDIPTAT-UHFFFAOYSA-N 0.000 description 1
- WBGNGAZJSTVCGF-UHFFFAOYSA-N acetic acid;2-[(3-bromo-4-methoxy-5-methylphenyl)methylideneamino]guanidine Chemical compound CC(O)=O.COC1=C(C)C=C(C=NN=C(N)N)C=C1Br WBGNGAZJSTVCGF-UHFFFAOYSA-N 0.000 description 1
- WXKJDNXETFDYLD-UHFFFAOYSA-N acetic acid;2-[(3-chloro-4-fluorophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.NC(N)=NN=CC1=CC=C(F)C(Cl)=C1 WXKJDNXETFDYLD-UHFFFAOYSA-N 0.000 description 1
- QXHRYVVURDNEBE-UHFFFAOYSA-N acetic acid;2-[(3-hydroxy-4-methyl-2-nitrophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.CC1=CC=C(C=NN=C(N)N)C([N+]([O-])=O)=C1O QXHRYVVURDNEBE-UHFFFAOYSA-N 0.000 description 1
- RHSRSSZJWYTEOM-UHFFFAOYSA-N acetic acid;2-[(4-bromo-2-fluoro-5-nitrophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.NC(N)=NN=CC1=CC([N+]([O-])=O)=C(Br)C=C1F RHSRSSZJWYTEOM-UHFFFAOYSA-N 0.000 description 1
- UUIQJIHFDPBYAR-UHFFFAOYSA-N acetic acid;2-[(4-bromo-2-fluorophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.NC(N)=NN=CC1=CC=C(Br)C=C1F UUIQJIHFDPBYAR-UHFFFAOYSA-N 0.000 description 1
- ULXODIFGXWJDAE-UHFFFAOYSA-N acetic acid;2-[(4-bromo-3-nitrophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.NC(N)=NN=CC1=CC=C(Br)C([N+]([O-])=O)=C1 ULXODIFGXWJDAE-UHFFFAOYSA-N 0.000 description 1
- WAQPKHNUTDJSKY-UHFFFAOYSA-N acetic acid;2-[(4-chloro-2-methoxy-5-nitrophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.COC1=CC(Cl)=C([N+]([O-])=O)C=C1C=NN=C(N)N WAQPKHNUTDJSKY-UHFFFAOYSA-N 0.000 description 1
- MOPSPQWIEOJJIG-UHFFFAOYSA-N acetic acid;2-[(4-chloro-3-fluorophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.NC(N)=NN=CC1=CC=C(Cl)C(F)=C1 MOPSPQWIEOJJIG-UHFFFAOYSA-N 0.000 description 1
- IMFGNFNOWZDLKV-UHFFFAOYSA-N acetic acid;2-[(4-fluoro-3-nitrophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.NC(N)=NN=CC1=CC=C(F)C([N+]([O-])=O)=C1 IMFGNFNOWZDLKV-UHFFFAOYSA-N 0.000 description 1
- OYRPZHBFIZLANB-UHFFFAOYSA-N acetic acid;2-[(4-methoxy-3-nitrophenyl)methylideneamino]guanidine Chemical compound CC(O)=O.COC1=CC=C(C=NN=C(N)N)C=C1[N+]([O-])=O OYRPZHBFIZLANB-UHFFFAOYSA-N 0.000 description 1
- GHHRHXOHRDBWHA-UHFFFAOYSA-N acetic acid;2-[(5-bromo-2,4-dimethoxyphenyl)methylideneamino]guanidine Chemical compound CC(O)=O.COC1=CC(OC)=C(C=NN=C(N)N)C=C1Br GHHRHXOHRDBWHA-UHFFFAOYSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0019357.3 | 2000-08-07 | ||
| GB0019357A GB0019357D0 (en) | 2000-08-07 | 2000-08-07 | Novel phenyl guanidines |
| PCT/GB2001/003534 WO2002011715A2 (en) | 2000-08-07 | 2001-08-07 | The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011148414A Division JP5683396B2 (ja) | 2000-08-07 | 2011-07-04 | ベンジリデンアミノグアニジンおよびヒドロキシグアニジンのメラノコルチン受容体リガンドとしての使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004505912A JP2004505912A (ja) | 2004-02-26 |
| JP2004505912A5 true JP2004505912A5 (enExample) | 2007-08-30 |
| JP5654190B2 JP5654190B2 (ja) | 2015-01-14 |
Family
ID=9897134
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002517052A Expired - Fee Related JP5654190B2 (ja) | 2000-08-07 | 2001-08-07 | ベンジリデンアミノグアニジンおよびヒドロキシグアニジンのメラノコルチン受容体リガンドとしての使用 |
| JP2011148414A Expired - Fee Related JP5683396B2 (ja) | 2000-08-07 | 2011-07-04 | ベンジリデンアミノグアニジンおよびヒドロキシグアニジンのメラノコルチン受容体リガンドとしての使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011148414A Expired - Fee Related JP5683396B2 (ja) | 2000-08-07 | 2011-07-04 | ベンジリデンアミノグアニジンおよびヒドロキシグアニジンのメラノコルチン受容体リガンドとしての使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (6) | US20040024060A1 (enExample) |
| EP (1) | EP1313461A2 (enExample) |
| JP (2) | JP5654190B2 (enExample) |
| KR (1) | KR100929363B1 (enExample) |
| AU (1) | AU2001276522A1 (enExample) |
| BR (1) | BR0113053A (enExample) |
| CA (1) | CA2417098A1 (enExample) |
| GB (1) | GB0019357D0 (enExample) |
| IL (2) | IL154272A0 (enExample) |
| MX (1) | MXPA03001072A (enExample) |
| WO (1) | WO2002011715A2 (enExample) |
| ZA (1) | ZA200300829B (enExample) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002000613A2 (en) * | 2000-06-27 | 2002-01-03 | Axxima Pharmaceuticals Ag | Inhibitors of hepatitis b virus infection |
| GB0019357D0 (en) | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel phenyl guanidines |
| GB0108631D0 (en) * | 2001-04-05 | 2001-05-30 | Melacure Therapeutics Ab | Novel benzylideneamino guanidines and their uses as ligands to the melanocortin receptors |
| GB0119172D0 (en) * | 2001-08-06 | 2001-09-26 | Melacure Therapeutics Ab | Phenyl pyrrole derivatives |
| US7344702B2 (en) | 2004-02-13 | 2008-03-18 | Bristol-Myers Squibb Pharma Company | Contrast agents for myocardial perfusion imaging |
| AU2002336638A1 (en) * | 2001-10-12 | 2003-04-28 | Cornell Research Foundation, Inc. | Reversing or preventing premature vascular senescence |
| AU2003219914A1 (en) * | 2002-02-25 | 2003-09-09 | Chiron Corporation | Intranasal administration of mc4-r agonists |
| US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| CA2551037A1 (en) | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivative |
| WO2005097127A2 (en) | 2004-04-02 | 2005-10-20 | Merck & Co., Inc. | Method of treating men with metabolic and anthropometric disorders |
| US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| ES2574014T3 (es) | 2005-05-30 | 2016-06-14 | Msd K.K. | Derivado de piperidina novedoso |
| AU2006277253A1 (en) | 2005-08-10 | 2007-02-15 | Msd K.K. | Pyridone compound |
| WO2007024004A1 (ja) | 2005-08-24 | 2007-03-01 | Banyu Pharmaceutical Co., Ltd. | フェニルピリドン誘導体 |
| AU2006288153A1 (en) | 2005-09-07 | 2007-03-15 | Msd K.K. | Bicyclic aromatic substituted pyridone derivative |
| KR20080048502A (ko) | 2005-09-29 | 2008-06-02 | 머크 앤드 캄파니 인코포레이티드 | 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체 |
| KR20080059233A (ko) | 2005-10-21 | 2008-06-26 | 노파르티스 아게 | 레닌 억제제, 및 항이상지질혈증제 및/또는 항비만제의조합물 |
| WO2007049798A1 (ja) | 2005-10-27 | 2007-05-03 | Banyu Pharmaceutical Co., Ltd. | 新規ベンゾオキサチイン誘導体 |
| BRPI0618354B8 (pt) | 2005-11-10 | 2021-05-25 | Banyu Pharma Co Ltd | composto e seu uso, composição farmacêutica, preventivo ou remédio |
| MX2008015454A (es) | 2006-06-09 | 2009-01-30 | Action Pharma As | Derivados de fenil-pirrol-aminoguanidina. |
| EP2698157B1 (en) | 2006-09-22 | 2015-05-20 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| US20090247560A1 (en) | 2006-09-28 | 2009-10-01 | Banyu Pharmaceutical Co., Ltd. | Diaryl ketimine derivative |
| GB0623381D0 (en) * | 2006-11-23 | 2007-01-03 | Acure Pharma Ab | Use of a compound as VEGF inhibitor |
| GB0624987D0 (en) * | 2006-12-14 | 2007-01-24 | Acure Pharma Ab | Novel aminoguanidines as melanocortin receptor ligands |
| PT2114873E (pt) | 2006-12-26 | 2013-05-06 | Lantheus Medical Imaging Inc | Ligandos para imagiologia de inervação cardíaca |
| WO2008120653A1 (ja) | 2007-04-02 | 2008-10-09 | Banyu Pharmaceutical Co., Ltd. | インドールジオン誘導体 |
| CN103601792B (zh) | 2007-06-04 | 2016-06-29 | 协同医药品公司 | 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂 |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| US8442179B2 (en) * | 2007-10-19 | 2013-05-14 | The Boeing Company | Method and apparatus for tagging and identifying a target |
| WO2009111037A2 (en) * | 2008-03-04 | 2009-09-11 | Indigene Pharmaceuticals Inc. | Compositions and methods for treating nos-associated diseases |
| WO2009110510A1 (ja) | 2008-03-06 | 2009-09-11 | 萬有製薬株式会社 | アルキルアミノピリジン誘導体 |
| CA2717384A1 (en) | 2008-03-28 | 2009-10-01 | Banyu Pharmaceutical Co., Ltd. | Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism |
| US20110071129A1 (en) | 2008-06-19 | 2011-03-24 | Makoto Ando | Spirodiamine-diaryl ketoxime derivative |
| ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
| JPWO2010013595A1 (ja) | 2008-07-30 | 2012-01-12 | Ｍｓｄ株式会社 | ５員−５員又は５員−６員縮環シクロアルキルアミン誘導体 |
| MX2011004258A (es) | 2008-10-22 | 2011-06-01 | Merck Sharp & Dohme | Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos. |
| CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US20110245209A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
| EP2379562A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
| US20120108668A1 (en) * | 2009-03-24 | 2012-05-03 | Lundstedt Erik Torbjoern | Metabolic profiles |
| NZ598124A (en) * | 2009-07-31 | 2014-01-31 | Anamar Ab | Compounds for treatment of inflammation |
| TWI664169B (zh) | 2010-02-08 | 2019-07-01 | 藍瑟斯醫學影像公司 | 用於合成造影劑及其中間體之方法及裝置 |
| CA2786314A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| MX367382B (es) | 2010-05-11 | 2019-08-19 | Lantheus Medical Imaging Inc | Composiciones, metodos y sistemas para la sintesis y el uso de agentes trazadores. |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| SG192941A1 (en) | 2011-02-25 | 2013-09-30 | Merck Sharp & Dohme | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| CN104159890B (zh) * | 2011-09-09 | 2018-04-10 | 蓝瑟斯医学影像公司 | 用于合成和使用显像剂的组合物、方法和系统 |
| KR20150036245A (ko) | 2012-08-02 | 2015-04-07 | 머크 샤프 앤드 돔 코포레이션 | 항당뇨병 트리시클릭 화합물 |
| AU2013203000B9 (en) | 2012-08-10 | 2017-02-02 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
| GB201300435D0 (en) * | 2013-01-10 | 2013-02-27 | Medical Res Council | Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases |
| MX2015010935A (es) | 2013-02-22 | 2015-10-29 | Merck Sharp & Dohme | Compuestos biciclicos antidiabeticos. |
| EP2970119B1 (en) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| US9486494B2 (en) | 2013-03-15 | 2016-11-08 | Synergy Pharmaceuticals, Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| EP4424697A3 (en) | 2013-06-05 | 2024-12-25 | Bausch Health Ireland Limited | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| EP3164391B1 (en) * | 2014-07-02 | 2019-07-31 | InFlectis BioScience | O-alkyl-benzylideneguanidine derivatives and therapeutic use for the treatment of disorders associated an accumulation of misfolded proteins |
| US10709677B2 (en) * | 2014-07-02 | 2020-07-14 | Inflectis Bioscience | Therapeutic uses of benzylideneguanidine derivatives for the treatment of proteopathies |
| JP6769963B2 (ja) | 2014-08-29 | 2020-10-14 | ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ | α−アミノ−β−カルボキシムコン酸セミアルデヒド脱炭酸酵素の阻害剤 |
| WO2016162689A1 (en) | 2015-04-08 | 2016-10-13 | Medical Research Council | Inhibitors and their uses |
| AU2017342083A1 (en) | 2016-10-14 | 2019-04-11 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
| EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| EP3558298A4 (en) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | ANTIDIABETIC SPIROCHROMAN COMPOUNDS |
| US20180230105A1 (en) | 2017-01-13 | 2018-08-16 | Regents Of The University Of Minnesota | Therapeutic compounds |
| CN108066763A (zh) * | 2017-12-21 | 2018-05-25 | 陈敏 | Pcsk9抑制剂在制备治疗t细胞介导的炎症免疫性疾病药中的应用 |
| JP2021529729A (ja) * | 2018-05-09 | 2021-11-04 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Ｉ型ｉｆｎ依存性病態を処置するためのグアナベンズ又はその誘導体の使用 |
| CA3119509A1 (en) | 2018-11-20 | 2020-05-28 | Tes Pharma S.R.L | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxxylase |
| SI3773558T1 (sl) | 2019-05-10 | 2022-11-30 | Synact Pharma Aps | Kombinirano zdravljenje artritične bolezni |
| CA3220753A1 (en) | 2021-06-21 | 2022-12-29 | Synact Pharma Aps | Salts of phenyl pyrrole aminoguanidine and polymorphs of phenyl pyrrole aminoguanidinium salts |
| US20240293343A1 (en) | 2023-02-13 | 2024-09-05 | Inflectis Bioscience | Benzylideneaminoguanidine derivatives as NR2B-selective NMDA receptor antagonists and their therapeutic applications |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2584784A (en) * | 1949-05-21 | 1952-02-05 | Du Pont | Salts of 1-salicylalaminoguanidine |
| GB892117A (en) | 1958-06-20 | 1962-03-21 | May & Baker Ltd | Phenanthridine salts and their preparation |
| DE1165013B (de) | 1960-08-09 | 1964-03-12 | Vismara Francesco Spa | Verfahren zur Herstellung von Guanylhydrazonen |
| GB923398A (en) | 1960-08-09 | 1963-04-10 | Vismara Francesco Spa | Diphenyl mono-and bis-formyl guanylhydrazones |
| GB1019120A (en) | 1964-03-18 | 1966-02-02 | Shell Int Research | Novel hydrazine compounds and compositions containing them |
| BE722109A (enExample) | 1967-10-12 | 1969-04-10 | ||
| GB1223492A (en) | 1967-10-13 | 1971-02-24 | American Home Prod | Guanidines |
| CH500953A (de) | 1967-11-13 | 1970-12-31 | Sandoz Ag | Verfahren zur Herstellung von neuen N-Benzyliden-N'-amidinohydrazinen |
| US3591636A (en) * | 1968-09-16 | 1971-07-06 | Sandoz Ag | Substituted benzylideneamino guanidines |
| GB1223493A (en) | 1968-10-11 | 1971-02-24 | American Home Prod | Guanidines |
| US3592852A (en) * | 1968-12-16 | 1971-07-13 | Sandoz Ag | Substituted benzylideneamino guanidine |
| DE2015321A1 (en) | 1969-04-04 | 1970-10-08 | Sandoz Ag, Basel (Schweiz) | Novel guanidine derivs |
| FR2036989A1 (en) * | 1969-04-28 | 1970-12-31 | Anvar | Amidino hydrazone antivirals |
| US3541218A (en) * | 1969-06-18 | 1970-11-17 | Lilly Co Eli | Omicron-fluorobenzylaminoguanidine for diabetes |
| US3592935A (en) * | 1969-12-11 | 1971-07-13 | Sandoz Ag | Substituted benzylidene hydrazines as anti-inflammatory agents |
| US3982020A (en) * | 1970-03-17 | 1976-09-21 | Sandoz, Inc. | Substituted benzylidene hydrazines for treating hyperglycemia, obesity and inflammation |
| US3975533A (en) * | 1970-04-29 | 1976-08-17 | Shell Oil Company | Therapeutic agents |
| US4060640A (en) * | 1970-04-29 | 1977-11-29 | Shell Oil Company | Therapeutic agents |
| JPS4842969B1 (enExample) | 1970-12-30 | 1973-12-15 | ||
| BE791536A (fr) | 1971-11-19 | 1973-05-17 | Merck & Co Inc | Nouvelles 1,3-diamino guanidines substituees |
| US3896232A (en) * | 1973-01-11 | 1975-07-22 | Sandoz Ag | Substituted benzylidene hydrazines as anti-migraine syndrome agents |
| US3941825A (en) * | 1973-07-27 | 1976-03-02 | American Cyanamid Company | Substituted aminobenzylideneamino guanidine compounds |
| US4006249A (en) * | 1975-08-06 | 1977-02-01 | American Home Products Corporation | Systemic treatment of psoriasis |
| US4006250A (en) * | 1975-08-25 | 1977-02-01 | American Home Products Corporation | Systemic treatment of psoriasis |
| FR2324294A1 (fr) | 1975-09-22 | 1977-04-15 | Roussel Uclaf | Nouveau medicament hypotenseur a action retardee, ainsi que le procede de preparation de ce nouveau medicament |
| GB1550401A (en) * | 1976-01-07 | 1979-08-15 | Hexachimie | Hydrazine derivatives their preparation and their use |
| DE2620369C3 (de) * | 1976-05-08 | 1979-01-04 | Bayer Ag, 5090 Leverkusen | Verfahren zur Wiedergewinnung von (l-S)-2-Oxo-bornansulfonat-(10) |
| US4312886A (en) * | 1978-07-20 | 1982-01-26 | American Home Products Corporation | Prevention of gastric ulcers and depression of gastric secretion by administration of guanabenz |
| JPS5562017A (en) | 1978-11-01 | 1980-05-10 | Teijin Ltd | Anti-inflammatory agent comprising guanidine derivative |
| US5958933A (en) * | 1982-11-23 | 1999-09-28 | Naftchi; N. Eric | Neurologically active compounds and compounds with multiple activities |
| US4983604A (en) | 1987-11-13 | 1991-01-08 | The Rockefeller University | Inhibitors of nonenzymatic cross-linking |
| ZA853488B (en) | 1984-05-10 | 1986-12-30 | American Home Prod | Transdermal dosage form |
| DE3428342A1 (de) * | 1984-08-01 | 1986-02-13 | Boehringer Ingelheim Vetmedica GmbH, 6507 Ingelheim | Futtermittelzusatz zur verbesserung des wachstums bei landwirtschaftlichen nutztieren |
| US6413962B1 (en) * | 1988-05-02 | 2002-07-02 | N. Eric Naftchi | Guanidino compounds effective as anesthetics |
| DE69130216T2 (de) | 1990-03-16 | 1999-03-25 | The Beth Israel Hospital Association, Boston, Mass. | Verwendung von spiperon als immunsuppressivum und antiinflammatorisches mittel |
| WO1992014453A1 (en) | 1991-02-26 | 1992-09-03 | Arc 1, Inc. | Compositions and methods of treatment of sympathetically maintained pain |
| HUT64023A (en) | 1991-03-22 | 1993-11-29 | Sandoz Ag | Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds |
| AU664710B2 (en) * | 1991-08-27 | 1995-11-30 | Upjohn Company, The | A method for treatment of metabolic disorders |
| US5696128A (en) | 1994-07-07 | 1997-12-09 | The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College | Method of regulating immune function |
| EP0710654A4 (en) * | 1993-07-23 | 1996-08-28 | Green Cross Corp | TRIAZOLE DERIVATIVE AND ITS PHARMACEUTICAL USE |
| US5599984A (en) * | 1994-01-21 | 1997-02-04 | The Picower Institute For Medical Research | Guanylhydrazones and their use to treat inflammatory conditions |
| EP0711553A1 (en) | 1994-08-09 | 1996-05-15 | Mario Cagnoni | Use of the Melatonin in the traetment of the articular symptoms of trheumatoid arthritis |
| US5559135A (en) * | 1994-09-14 | 1996-09-24 | Merck & Co., Inc. | Endothelin antagonists bearing pyridyl amides |
| AU2629795A (en) * | 1994-12-12 | 1996-07-03 | Chugai Seiyaku Kabushiki Kaisha | Aniline derivative having the effect of inhibiting nitrogen monoxide synthase |
| US5602277A (en) | 1995-03-30 | 1997-02-11 | Biocryst Pharmaceuticals, Inc. | Substituted benzene derivatives useful as neuraminidase inhibitors |
| US5958934A (en) | 1996-05-23 | 1999-09-28 | Syntex (U.S.A.) Inc. | Aryl pyrimidine derivatives and uses thereof |
| SE9604348D0 (sv) * | 1996-11-26 | 1996-11-26 | Wapharm Ab | Användning av hydroxyguanidiner |
| WO1999021571A1 (en) | 1997-10-27 | 1999-05-06 | Trega Biosciences, Inc. | Melanocortin receptor ligands and methods of using same |
| WO1999052936A2 (en) | 1998-04-09 | 1999-10-21 | Eisai Co., Ltd. | Arginine peptide analogs useful as fibroblast growth factor antagonists |
| EP1076649A4 (en) | 1998-04-28 | 2010-06-02 | Trega Biosciences Inc | ISOQUINOLINE-BASED COMPOUNDS IN PLACE OF MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USE |
| AU742425B2 (en) | 1998-06-11 | 2002-01-03 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
| WO2000009115A1 (en) | 1998-08-14 | 2000-02-24 | Smithkline Beecham Corporation | Grp receptor ligands |
| GB9827500D0 (en) | 1998-12-14 | 1999-02-10 | Wapharm Ab | Compounds for control of eating, growth and body weight |
| US6544541B1 (en) | 1999-06-02 | 2003-04-08 | Cardiovascular Solutions, Inc. | Devices and compounds for treating arterial restenosis |
| WO2001005401A1 (en) | 1999-07-16 | 2001-01-25 | Trega Biosciences, Inc. | Melanocortin receptor-3 ligands to treat sexual dysfunction |
| US6503950B1 (en) | 1999-08-23 | 2003-01-07 | David M. Ockert | Triple drug therapy for the treatment of narcotic and alcohol withdrawal symptoms |
| WO2001025192A1 (en) * | 1999-10-06 | 2001-04-12 | Melacure Therapeutics Ab | Guanidine derivatives and their use in the production of a medicament for blocking xanthine oxidase/dehydrogenase |
| GB0019357D0 (en) * | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel phenyl guanidines |
| GB0019359D0 (en) | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel guanidines |
| GB0108631D0 (en) | 2001-04-05 | 2001-05-30 | Melacure Therapeutics Ab | Novel benzylideneamino guanidines and their uses as ligands to the melanocortin receptors |
| GB0119172D0 (en) * | 2001-08-06 | 2001-09-26 | Melacure Therapeutics Ab | Phenyl pyrrole derivatives |
| US7060711B2 (en) | 2001-10-25 | 2006-06-13 | Biofrontera Bioscience Gmbh | Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist |
| GB0622826D0 (en) * | 2006-11-15 | 2006-12-27 | Acurepharma Ab | Novel amides acting on the adenosine receptors |
| GB0624987D0 (en) * | 2006-12-14 | 2007-01-24 | Acure Pharma Ab | Novel aminoguanidines as melanocortin receptor ligands |
-
2000
- 2000-08-07 GB GB0019357A patent/GB0019357D0/en not_active Ceased
-
2001
- 2001-08-07 KR KR20037001846A patent/KR100929363B1/ko not_active Expired - Fee Related
- 2001-08-07 IL IL15427201A patent/IL154272A0/xx unknown
- 2001-08-07 CA CA 2417098 patent/CA2417098A1/en not_active Abandoned
- 2001-08-07 EP EP20010954176 patent/EP1313461A2/en not_active Withdrawn
- 2001-08-07 US US10/343,325 patent/US20040024060A1/en not_active Abandoned
- 2001-08-07 AU AU2001276522A patent/AU2001276522A1/en not_active Abandoned
- 2001-08-07 MX MXPA03001072A patent/MXPA03001072A/es active IP Right Grant
- 2001-08-07 BR BR0113053A patent/BR0113053A/pt not_active Application Discontinuation
- 2001-08-07 WO PCT/GB2001/003534 patent/WO2002011715A2/en not_active Ceased
- 2001-08-07 JP JP2002517052A patent/JP5654190B2/ja not_active Expired - Fee Related
-
2003
- 2003-01-30 ZA ZA200300829A patent/ZA200300829B/xx unknown
- 2003-02-03 IL IL15427203A patent/IL154272A/en not_active IP Right Cessation
-
2006
- 2006-12-15 US US11/639,190 patent/US8148429B2/en not_active Expired - Fee Related
-
2007
- 2007-05-16 US US11/798,669 patent/US20070231267A1/en not_active Abandoned
-
2010
- 2010-09-28 US US12/892,402 patent/US8309609B2/en not_active Expired - Fee Related
-
2011
- 2011-07-04 JP JP2011148414A patent/JP5683396B2/ja not_active Expired - Fee Related
-
2012
- 2012-03-21 US US13/426,096 patent/US8410174B2/en not_active Expired - Fee Related
-
2013
- 2013-03-14 US US13/803,555 patent/US9227927B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004505912A5 (enExample) | ||
| JP2004505947A5 (enExample) | ||
| EP1797878A3 (en) | Benzothiazole derivatives | |
| TR200001795T2 (tr) | 1-İkameli-1-Aminometil-sikloalkan türevleri (=Gabapentin analogları), bunların hazırlanması ve nörolojik bozuklukların tedavisinde kullanımı. | |
| JP2005516967A5 (enExample) | ||
| CA2349142A1 (en) | Compositions and methods for stimulating gastrointestinal motility | |
| BR0213358A (pt) | Uso de flibanserina | |
| DK1404331T3 (da) | Sustained release-formuleringer af oxymorphon | |
| JP2005525345A5 (enExample) | ||
| JP2010523477A5 (enExample) | ||
| JP2004500426A5 (enExample) | ||
| JP2010507593A5 (enExample) | ||
| JP2007526238A5 (enExample) | ||
| JP2002535370A5 (enExample) | ||
| RU2007106930A (ru) | Производные хиназолина | |
| JP2022512826A (ja) | ＭｅｔＡＰ２阻害剤のバイオマーカーとその応用 | |
| JPH10147529A5 (enExample) | ||
| RU2004136999A (ru) | Способы лечения болевых расстройств желудочно-кишечной и мочеполовой систем, использующие венлфаксин и его производные | |
| EP1431286A3 (en) | Prodigiosin derivatives for treating cancer or viral diseases | |
| CA2389032A1 (en) | Preventive or therapeutic agents for inflammatory diseases of intestine | |
| MY133512A (en) | Non-steroidal il-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors | |
| JP2002506864A5 (enExample) | ||
| CA2373634A1 (en) | Isophosphoramide mustard analogs and use thereof | |
| BR9504230A (pt) | Composto composiçao farmacêutica método para o tratamento ou prevençao de uma doença e utilizaçao de um composto | |
| JP2006510659A5 (enExample) |